Agenus says presents results from two cervical cancer trials at esmo

Agenus presents results from two large cervical cancer trials at esmo.agenus inc - 160 patient balstilimab (pd-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in pd-l1 positive patients.agenus -155 patient balstilimab (pd-1) + zalifrelimab combination trial achieves response rates of 22% in all patients&27% in pd-l1 positive patients.agenus inc - both trials conducted in patients with recurrent/metastatic cervical cancer.agenus inc - these trials show that balstilimab and zalifrelimab may present meaningful new therapies for patients with cervical cancer.
AGEN Ratings Summary
AGEN Quant Ranking